Zinbryta (daclizumab) Withdrawn from Global Markets
- Dennis M. Biogen, AbbVie withdraw multiple sclerosis therapy Zinbryta from market. FirstWord Pharma. March 2, 2018. Accessed online March 5, 2018. Available from: https://www.firstwordpharma.com/node/1546123
- Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis. Biogen. March 2, 2018. Accessed online March 5, 2018.